Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy in Advanced DLBCL
NCT05874778Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2023
- Primary completion
- May 2026
01
Overview
Phase 2, randomised, open-label trial (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoints: Event-Free Survival Rate at 2 years and Progression-Free Survival Rate at 2 years. Planned start May 2023; status: not yet recruiting.
Beyond the preview
Go deeper on NCT05874778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05874778.